NeuroOne Medical Technologies Corp (NMTC) Stock Analysis

AI analysis of NeuroOne Medical Technologies Corp (NMTC)

Hold

Neuroone Medical Technologies Corp is currently not a strong buy due to its recent performance and financial challenges, despite some positive indicators. The current price is $0.8501, with an RSI of 40.595 indicating it is nearing oversold territory. However, the company has seen a significant year-to-date change of -83.38% and a 20-day change of -24.10%, which raises concerns about its short-term viability. While the gross margin has improved to 59.94%, the company continues to report losses, with a net income of -$2,006,331 in Q3 2026. The main risk is its deteriorating cash position, which has dropped from $6.6 million to $2.8 million, potentially limiting its operational capacity.

Valuation Metrics

The current forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC) is 0.00, compared to its 5-year average forward P/E of -2.80.

Forward P/E

Strongly Overvalued

5Y Average P/E

-2.80

Current P/E

0.00

Overvalued

-1.71

Undervalued

-3.90

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-1.33

Current EV/EBITDA

-0.36

Overvalued

-0.25

Undervalued

-2.40

Forward P/S

Fair

5Y Average P/S

13.30

Current P/S

0.59

Overvalued

44.13

Undervalued

-17.53

NMTC FAQ — answered by Alphio AI

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Neuroone Medical Technologies Corp is currently not a strong buy due to its recent performance and financial challenges, despite some positive indicators. The current price is $0.8501, with an RSI of 40.595 indicating it is nearing oversold territory. However, the company has seen a significant year-to-date change of -83.38% and a 20-day change of -24.10%, which raises concerns about its short-term viability. While the gross margin has improved to 59.94%, the company continues to report losses, with a net income of -$2,006,331 in Q3 2026. The main risk is its deteriorating cash position, which has dropped from $6.6 million to $2.8 million, potentially limiting its operational capacity.